LESCOL
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LESCOL by Novartis is hmg-coa reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) to mevalonate, a precursor of cholesterol. First approved in 1993.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LESCOL (fluvastatin) is an oral HMG-CoA reductase inhibitor (statin) approved in 1993 for cholesterol management. It works by blocking the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and triglycerides. The drug is indicated for patients with elevated cholesterol who require pharmacologic intervention to reduce cardiovascular risk.
LOE Approaching
Declining
Product approaching loss of exclusivity with moderate competitive pressure (30/100); smaller team structures expected as market transitions to generics.
Mechanism of Action
HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LESCOL in 2024 involves managing a product in late decline with no linked job openings identified. Career opportunities are concentrated in generic defense, payer negotiations, and portfolio rationalization rather than growth-focused roles.
Generic Strategy ManagerMedical Science Liaison (legacy support)
Worked on LESCOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.